Opening stock page...
Fetching company snapshot, pricing, and intelligence.
Intelligence coverage: 60%
Basic profile, financials, and market data are shown below. Deep research is building in the background.
AI confidence 71% · prior close shown (market closed)
Vericel Corp shows stable business momentum based on AlphaOS pipeline evidence.
Why it matters: Revenue +22% YoY in Q2 FY2026.
3 signals not yet derived from pipeline evidence
What it means for the thesis — synthesis, not a raw event feed.
Pipeline evidence · 22d ago
VCEL's AlphaOS Signals
Upgrade to Pro for validated historical pattern analysis on VCEL.
Free accounts see more of this; Premium sees all of it.
Reported figures for Vericel Corp — research only, not investment advice.
Updated
What happened recently for Vericel Corp (VCEL) — events, not interpretation.
Research & analysis only — not investment advice.
Held in ETFsweight · est. sleeve dollars
VCEL's AI investment thesis
Upgrade to Premium for VCEL's full multi-agent investment thesis.
Free accounts see more of this; Premium sees all of it.
Unified data coverage and cross-signal highlights — market, SEC, earnings, opportunity
Strengthen intelligence
Prior close
$38.79
Market cap
$1.99B
Profitable
Yes
Revenue $77.46M
Net income
$2.21M
FY Sep 12, 2026
Loading Wall Street consensus…
Loading earnings intelligence…
Building technical intelligence snapshot — check back shortly.
Loading market context…
No price history. Sync market data to load charts.
Loading SEC filing intelligence…
No filings ingested yet.
Healthcare · Biological Products, (No Diagnostic Substances)
Investment Snapshot above is the primary AlphaOS analysis for Vericel Corp — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.
Research & analysis only — not investment advice. Price, charts, and filings are above.
Follow Vericel Corp through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.
Connected companies and research pages from the AlphaOS knowledge graph.